clinical trial
Gene therapy trial for dry AMD under way in Australia
Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre ...
Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
Australian glaucoma trial set to expand after vitamin B3 success
Daily doses of vitamin B3 can lead to significant improvements in glaucoma patients who are also receiving regular treatments to ...
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the ...